# A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).

> **NCT00863746** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 703 (actual)

## Conditions studied

- Carcinoma
- Non-Small-Cell Lung

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00863746
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2012-03
- **Final completion:** 2013-04
- **Target enrollment:** 703 (ACTUAL)
- **Last updated:** 2015-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00863746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00863746, "A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00863746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*